| Budget Amount *help |
¥3,300,000 (Direct Cost: ¥3,300,000)
Fiscal Year 2001: ¥1,500,000 (Direct Cost: ¥1,500,000)
Fiscal Year 2000: ¥1,800,000 (Direct Cost: ¥1,800,000)
|
|---|
| Research Abstract |
At the site of vascular injury, von Willebrand factor (VWF) mediates platelet adhesion to subendothelial connective tissue through binding to N-terminal VWF binding region of the a chain of platelet glycoprotein Ib-V-IX complex (GPIbα). The detailed molecular mechanisms responsible for GPIbα binding of VWF remain to be elucidated. In order to provide a direct answer to this question, we have employed charged-to-alanine scanning mutagenesis to define functional amino acid residues of the N-terminal 302 amino acids of GPIbα. Sixty six charged amino acids including arginine, lysine, aspartate, glutamate, and histidine were changed singly or in small clusters to alanine between 1 and 302 of human GPIbα. Recombinant mutants were assayed for binding to several conformation-dependent monoclonal antibodies to GPIbα, for ristocetin-induced and botrocetin-induced binding of 1251-labeled human VWF. Forty mutant constructs expressing a soluble fragment of GPIbα a were produced according with FLAG-tag at the C-terminal end. Mutations at 128, 172, 175, 217, and 218 decreased both ristocetin- and botrocetin-induced VWF binding. In contrast, mutations at 12 and 14 decreased the ristocetin-dependent VWF binding with normal botrocetin-induced binding. Three recombinant proteins mutated at 217, 218 285, 287, and 301reduced only the botrocetin induced VWF binding. Monoclonal antibody (Mab) 6D1 inhibits ristocetin and botrocetin-induced VWF binding and a mutation at Glul25 specifically reduced the binding to 6D1. In contrast, Mab HPL7 has no effect for VWF binding and a mutation at 121 reduced the binding.
|
